Roche Holding | ROG - Current Assets


Roche Holding reported CHF35.44B in Current Assets for its fiscal semester ending in June of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Alcon AG USD 6.62B 4M Jun/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amgen USD 34.36B 598M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Fresenius EUR 12.29B 678M Sep/2026
Fresenius Medical Care EUR 7.84B 150.6M Sep/2026
Genmab DKK 2.8B 228M Jun/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
GRIFOLS EUR 5.35B 40M Sep/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 15.14B 1.37B Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Orion EUR 1.34B 139.5M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Philips EUR 10.51B 1.18B Sep/2026
Recordati EUR 1.89B 128.35M Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026
UCB EUR 6.05B 733M Dec/2025